Key Takeaways
- • Fresenius launches Fresenius Ventures, a corporate venture capital fund with €200 million+ (US$228 million) committed capital over five years, targeting early-stage through growth-stage healthcare innovators aligned with its strategic platforms.
- • Investment focus areas include precision nutrition, microbiome research, new drug modalities, and digital care provision solutions—all adjacent to Fresenius' existing Bio(Pharma), MedTech, and Care Provision business units.
- • Dr. Thomas Michael Thestrup, a 15+ year healthcare and corporate venture capital veteran, heads the fund; he joins from Angelini Ventures with prior roles at Lundbeck, UCB, and Sunstone Capital.
- • The venture fund is positioned as a core pillar of #FutureFresenius strategy, combining capital deployment with integrated medical, regulatory, operational, and clinical-scientific expertise to accelerate breakthrough technology access and adjacent market expansion.
- • Investment allocation will follow Fresenius' established capital discipline framework, with the fund operating as a strategic instrument to strengthen innovation capabilities across the healthcare ecosystem.
Summary
Fresenius, the Germany-based therapy-focused healthcare company, has established Fresenius Ventures, a corporate venture capital fund designed to strengthen its access to innovation networks and emerging technologies. The newly created unit represents a structural expansion of the company's innovation strategy, with an intended investment volume exceeding €200 million (US$228 million) to be deployed over the next five years across early-stage through growth-stage healthcare companies.
The fund's investment thesis focuses on four primary sectors adjacent to Fresenius' core business platforms: precision nutrition, microbiome research, new drug modalities, and digital care provision solutions. These areas complement Fresenius' existing strategic platforms in Bio(Pharma), MedTech, and Care Provision. By combining venture capital with embedded medical, regulatory, and operational expertise, along with access to clinical, scientific, and academic networks, the fund aims to provide portfolio companies with resources beyond capital—including pathway guidance to commercialization and clinical validation.
CEO Michael Sen framed the venture fund as integral to the company's #FutureFresenius strategic initiative, stating that targeted investments in healthcare innovators will provide "early access to breakthrough technologies, new ideas, and entrepreneurial talent" while strengthening innovation capabilities and enabling expansion into adjacent growth fields. The fund's capital deployment will adhere to Fresenius' established capital allocation discipline.
Leadership of Fresenius Ventures has been assigned to Dr. Thomas Michael Thestrup, who brings 15+ years of healthcare and corporate venture capital experience. Thestrup most recently served at Angelini Ventures and previously held positions as director of Corporate Business Development and Strategy at Lundbeck, as well as roles in Global Business Development at UCB and Life Science Ventures at Sunstone Capital. This leadership profile underscores the fund's focus on integrating operational and industry expertise alongside capital deployment.
The venture fund launch signals Fresenius' commitment to institutional innovation sourcing, moving beyond organic R&D to capture external technologies and business model innovations at scale. This approach aligns with broader industry trends among large healthcare incumbents establishing dedicated venture arms to maintain competitive positioning in rapidly evolving therapeutic and digital health segments.
The fund's investment thesis focuses on four primary sectors adjacent to Fresenius' core business platforms: precision nutrition, microbiome research, new drug modalities, and digital care provision solutions. These areas complement Fresenius' existing strategic platforms in Bio(Pharma), MedTech, and Care Provision. By combining venture capital with embedded medical, regulatory, and operational expertise, along with access to clinical, scientific, and academic networks, the fund aims to provide portfolio companies with resources beyond capital—including pathway guidance to commercialization and clinical validation.
CEO Michael Sen framed the venture fund as integral to the company's #FutureFresenius strategic initiative, stating that targeted investments in healthcare innovators will provide "early access to breakthrough technologies, new ideas, and entrepreneurial talent" while strengthening innovation capabilities and enabling expansion into adjacent growth fields. The fund's capital deployment will adhere to Fresenius' established capital allocation discipline.
Leadership of Fresenius Ventures has been assigned to Dr. Thomas Michael Thestrup, who brings 15+ years of healthcare and corporate venture capital experience. Thestrup most recently served at Angelini Ventures and previously held positions as director of Corporate Business Development and Strategy at Lundbeck, as well as roles in Global Business Development at UCB and Life Science Ventures at Sunstone Capital. This leadership profile underscores the fund's focus on integrating operational and industry expertise alongside capital deployment.
The venture fund launch signals Fresenius' commitment to institutional innovation sourcing, moving beyond organic R&D to capture external technologies and business model innovations at scale. This approach aligns with broader industry trends among large healthcare incumbents establishing dedicated venture arms to maintain competitive positioning in rapidly evolving therapeutic and digital health segments.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.